(Press-News.org) PHILADELPHIA — Allopurinol, a relatively inexpensive anti-gout medication that has been on the market for more than 20 years, may have some activity against colorectal adenomas, according to data presented at the Ninth Annual AACR Frontiers in Cancer Prevention Research Conference, held here Nov. 7-10, 2010.
Specifically, the presence of a colorectal tumor tissue biomarker, Ki67, was markedly decreased in the preliminary results of a study of patients with colorectal polyps assigned to take allopurinol.
"Allopurinol has a well-known and good safety profile, and a cost of approximately one euro for one month of treatment," said Andrea De Censi, M.D., director, medical oncology unit, Galliera Hospital, Genoa, and advisor, division of cancer prevention and genetics, EIO, Milan, Italy.
"In the era of very expensive target-therapy in oncology, it is important to search for cheap
agents that could be active in cancer prevention and thus have huge public health implications,"
he said.
In colorectal tumor tissue there are high levels of ROM, or reactive oxygen metabolites.
"These ROMs are thought to be important for development of tumor tissue and carcinogenesis. It is known today that ROMs activate crucial processes involved in cell growth, and in processes that inhibit programmed cell death, one of the main mechanisms involved in cancer control," De Censi said.
Therefore, researchers are testing the effect of ROM scavengers, such as allopurinol, to measure their effects on chemoprevention. According to De Censi, previous research from a large case-control study conducted in Israel showed that patients under chronic allopurinol use for gout had a lower risk for colorectal cancer than a matched control group not using allopurinol.
In the current study, De Censi and colleagues conducted a Phase I/II double-blind, placebo-controlled trial of patients with colorectal adenomatous polyps. Between 2006 and 2010, 73 patients were enrolled and assigned placebo or either a 100-mg or 300-mg dose of allopurinol for four to six weeks prior to removal of polyps.
They collected normal and adenomatous tissue samples and measured changes in the biomarker Ki67 in the normal tissue and the adenomatous tissue to measure the effect of allopurinol. At an interim analysis, conducted in November of 2008, only three mild adverse gastrointestinal events had occurred, confirming the high safety profile of allopurinol.
Tissue analysis in the first 13 patients indicated that levels of Ki67 in normal tissue had doubled in patients taking placebo, but had only increased by 5 percent in patients taking either dose of allopurinol.
In adenoma tissue, levels of Ki67 increased by 70 percent in patients taking placebo compared with only 6 percent in patients taking 100 mg allopurinol and 12 percent in patients taking 300 mg allopurinol.
"Our findings need to be confirmed on a larger number of subjects. However, if the positive trend noted on Ki67 is confirmed, we will conclude that allopurinol has some activity against colon carcinogenesis that may explain the favorable trend noted in the epidemiological studies. These results will provide the background for a large trial of adenoma recurrence reduction with allopurinol," De Censi said.
###
Download interviews with cancer researchers and recordings of teleconferences by subscribing to the AACR Scientific Podcasts via iTunes (http://www.aacr.org/itunes) or an RSS Reader (http://www.aacr.org/rss).
Follow the AACR on Twitter: @AACR #AACR
Follow the AACR on Facebook: http://www.facebook.com/aacr.org
The mission of the American Association for Cancer Research is to prevent and cure cancer. Founded in 1907, the AACR is the world's oldest and largest professional organization dedicated to advancing cancer research. The membership includes 32,000 basic, translational and clinical researchers; health care professionals; and cancer survivors and advocates in the United States and more than 90 other countries. The AACR marshals the full spectrum of expertise from the cancer community to accelerate progress in the prevention, diagnosis and treatment of cancer through high-quality scientific and educational programs. It funds innovative, meritorious research grants, research fellowships and career development awards. The AACR Annual Meeting attracts more than 18,000 participants who share the latest discoveries and developments in the field. Special conferences throughout the year present novel data across a wide variety of topics in cancer research, treatment and patient care. Including Cancer Discovery, the AACR publishes seven major peer-reviewed journals: Cancer Research; Clinical Cancer Research; Molecular Cancer Therapeutics; Molecular Cancer Research; Cancer Epidemiology, Biomarkers & Prevention; and Cancer Prevention Research. AACR journals represented 20 percent of the market share of total citations in 2009. The AACR also publishes CR, a magazine for cancer survivors and their families, patient advocates, physicians and scientists.
Anti-gout drug may decrease risk for colorectal adenoma progression
2010-11-09
ELSE PRESS RELEASES FROM THIS DATE:
Statins did not reduce colorectal cancer in WHI analysis
2010-11-09
PHILADELPHIA — The use of statins among a group of postmenopausal women did not reduce the risk for colorectal cancer, according to the results of a prospective analysis of data from the large population-based Women's Health Initiative (WHI).
"The results of our study are consistent with the majority of the literature suggesting no significant reduction in colorectal cancer risk among users of statins," said Michael S. Simon, M.D., professor of oncology in the department of oncology at Wayne State University and Barbara Ann Karmanos Cancer Institute, Detroit.
Simon ...
Soy isoflavones may modify risk of breast cancer
2010-11-09
PHILADELPHIA — Increased phytoestrogens commonly found in dietary soy may modify the risk of some types of breast cancer, according to findings presented at the Ninth Annual AACR Frontiers in Cancer Prevention Research Conference, held Nov. 7-10, 2010.
"This study was unique in that we looked at specific subtypes of breast cancer, and found a suggestion that menopausal status may play a role in risk," said Anne Weaver, a graduate student at the University at Buffalo and research apprentice at Roswell Park Cancer Institute.
Weaver and colleagues evaluated 683 women ...
Could lung cancer in smokers vs. 'never-smokers' be different diseases?
2010-11-09
PHILADELPHIA — Lung tumors in those who smoke and those who never smoked have different DNA alterations in the tumor genomes, according to results of a pilot study presented at the Ninth Annual AACR Frontiers in Cancer Prevention Research Conference, held Nov. 7-10, 2010, in Philadelphia.
Based on the results of this study, Kelsie Thu, a Ph.D. candidate at the BC Cancer Research Center in Vancouver, Canada, suggested that "lung cancer in never-smokers should be studied as a separate group," and that lung cancers in smokers and never-smokers may represent two different ...
Smoking increased risk of death in women with breast cancer
2010-11-09
PHILADELPHIA — Being a current smoker or having a history of smoking significantly increased the risk of breast cancer progression and overall death among a group of multiethnic women with breast cancer, according to the results of a large prospective cohort study.
"We found that women who are current smokers or have history of smoking had a 39 percent higher rate of dying from breast cancer, even after we took into account a wide array of known prognostic factors including clinical, socioeconomic and behavioral factors," said Dejana Braithwaite, Ph.D, assistant professor, ...
Obesity not linked to breast cancer in Mexican-American women
2010-11-09
PHILADELPHIA — Obesity was not associated with breast cancer risk in Mexican-American women, even when measured at numerous ages throughout a woman's lifetime, according to data presented at the Ninth Annual AACR Frontiers in Cancer Prevention Research Conference, held here Nov. 7-10, 2010.
However, data did show that weight gain during adulthood seemed to reduce breast cancer risk, regardless of menopausal status.
"We found that for every 5 kg of weight gain there was a significant 8 percent decrease in the risk for breast cancer," said Krystal Sexton, Ph.D., a ...
A comparison of severe outcomes during the waves of pandemic (H1N1) 2009
2010-11-09
The second wave of the pandemic (H1N1) was substantially greater than the first with 4.8 times more hospital admissions, 4.6 times more deaths and 4 times more ICU cases, according to a study published in CMAJ (Canadian Medical Association Journal) (pre-embargo link only) http://www.cmaj.ca/embargo/cmaj100746.pdf. However, because of the larger number of people hospitalized during the second wave compared to the first, the percentage of people with severe outcomes was smaller.
The researchers compared demographic and clinical characteristics as well as outcomes of patients ...
Do not abandon new cigarette warning labels
2010-11-09
Health Canada's cancellation of plans to renew tobacco warning labels on cigarette packages may lead to increased smoking rates and smoking-related illnesses and deaths, states an editorial in CMAJ (Canadian Medical Association Journal) (pre-embargo link only) http://www.cmaj.ca/embargo/cmaj101583.pdf.
Ten years ago, Canada was a leader in warning labels and other effective tobacco policies. Abandoning this labeling policy may be a set back for efforts in Canada, particularly as labels are now the government's only remaining mass communication initiative warning of the ...
Differences in human and Neanderthal brains set in just after birth
2010-11-09
The findings are based on comparisons of virtual imprints of the developing brain and surrounding structures (known as endocasts) derived from the skulls of modern and fossilized humans, including that of a newborn Neanderthal.
Philipp Gunz of the Max Planck Institute for Evolutionary Anthropology explained that the differences researchers observe in early brain development likely reflect changes in the underlying brain circuitry. It is that internal organization of the brain that matters most for cognitive ability.
"In modern humans, the connections between diverse ...
Fusion makes major step forward at MIT through studies of the plasma edge
2010-11-09
###
These new findings will be presented in three invited talks at the American Physical Society, Division of Plasma Physics 52nd annual meeting on November 8-12 in Chicago. END ...
Getting to know the sun advances fusion research
2010-11-09
Researchers at the Princeton Plasma Physics Laboratory have successfully used Coaxial Helicity Injection (CHI) to generate plasma current and couple it to a conventional current generation method at the National Spherical Torus Experiment (NSTX) fusion experiment. After coupling, the combined process generated 1 million amperes of current using 40 percent less energy than needed to generate this current using the conventional means by itself, thus demonstrating that a high-quality initial magnetic configuration was produced by CHI.
Plasma confinement devices based on ...